公开(公告)号：US20210054057A1

公开(公告)日：2021-02-25

申请号：US16895471

申请日：2020-06-08

Applicant: H. Lundbeck A/S

Inventor： Pekka KALLUNKI ,  Karina FOG ,  Louise Buur VESTERAGER ,  Ann-Louise BERGSTRÔM ,  Florence SOTTY ,  David SATIJN ,  Edward VAN DEN BRINK ,  Paul PARREN ,  Rik RADEMAKER ,  Tom VINK ,  Ibrahim John MALIK ,  Liliana Christina Pereira MONTEZINHO

IPC: C07K16/18 ,  A61K51/00 ,  A61K39/395 ,  A61P25/16 ,  A61P25/28 ,  G01N33/68

Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.

公开(公告)号：US20210047342A1

公开(公告)日：2021-02-18

申请号：US16916681

申请日：2020-06-30

Applicant: H. Lundbeck A/S

Inventor： John Paul Kilburn ,  Erhad Ascic ,  Mauro Marigo ,  Laurent David

IPC: C07D495/04

Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

公开(公告)号：US20210015794A1

公开(公告)日：2021-01-21

申请号：US17060796

申请日：2020-10-01

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Karsten Juhl ,  Mauro Marigo ,  Paulo Jorge Vieira Vital ,  Mikkel Jessing ,  Morten Langgård ,  Lars Kyhn Rasmussen ,  Carl Martin Sebastian Clementson

IPC: A61K31/4162 ,  C07D471/04 ,  A61K31/4745 ,  C07D413/04

Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (1) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

公开(公告)号：US20210009571A1

公开(公告)日：2021-01-14

申请号：US16955926

申请日：2018-12-19

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Lars Kyhn Rasmussen ,  Morten Langgârd ,  Mikkel Jessing ,  Paulo Jorge Vieira Vital ,  Karsten Juhl ,  Mauro Marigo

IPC: C07D405/14 ,  C07D401/14

Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

公开(公告)号：US10800836B2

公开(公告)日：2020-10-13

申请号：US15207859

申请日：2016-07-12

Applicant: H. Lundbeck A/S

Inventor： Pekka Kallunki ,  Karina Fog ,  Louise Buur Vesterager ,  Ann-Louise Bergstrôm ,  Florence Sotty ,  David Satijn ,  Edward van den Brink ,  Paul Parren ,  Rik Rademaker ,  Tom Vink ,  Ibrahim John Malik ,  Liliana Christina Pereira Montezinho

IPC: C07K16/18 ,  A61K39/395 ,  A61K51/00 ,  A61P25/16 ,  A61P25/28 ,  G01N33/68 ,  A61K39/00

Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.

公开(公告)号：US10729710B2

公开(公告)日：2020-08-04

申请号：US16198917

申请日：2018-11-23

Applicant: H. Lundbeck A/S

Inventor： Klaus Gjervig Jensen ,  Lisbet Kværnø ,  Morten Jørgensen ,  Martin Juhl

IPC: A61K31/706 ,  A61K31/473 ,  A61P25/00 ,  C07D405/12 ,  C07D405/14

Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.Accordingly, the present invention relates to compounds of formula (Id) wherein R1 is H and R2 is selected from one of the substituents (i) and (ii) below; or R1 is selected from one of the substituents (i) and (ii) below and R2 is H; or R1 and R2 are both represented by substituent (i) below; or R1 and R2 are both represented by substituent (ii) below; or R1 is substituent (i) and R2 is substituent (ii); or R1 is substituent (ii) and R2 is substituent (i); wherein * indicates the attachment point; and wherein the carbon atom at the attachment point on substituent (i) is in the S-configuration; or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200163959A1

公开(公告)日：2020-05-28

申请号：US16502677

申请日：2019-07-03

Applicant: H. Lundbeck A/S

Inventor： André Faldt ,  Heidi Lopez de Diego ,  Rene Holm

IPC: A61K31/495 ,  A61K9/14 ,  C07D295/096

Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

公开(公告)号：US20200030319A1

公开(公告)日：2020-01-30

申请号：US16291865

申请日：2019-03-04

Applicant: H. Lundbeck A/S

Inventor： Connie Sanchez Morillo ,  Karina Krøjer Søby ,  Benny Bang-Andersen

IPC: A61K31/495 ,  A61K9/00 ,  A61K9/08 ,  A61K47/40

Abstract: A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.

公开(公告)号：US20190352302A1

公开(公告)日：2019-11-21

申请号：US16424585

申请日：2019-05-29

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Lars Kyhn Rasmussen ,  Morten Langgård ,  Mikkel Jessing ,  Paulo Jorge Vieira Vital ,  Karsten Juhl ,  Mauro Marigo

IPC: A61K31/502 ,  C07D471/04 ,  C07D519/00 ,  C07D487/04 ,  A61P25/28 ,  A61P25/00 ,  A61P25/18 ,  A61P25/16

Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

公开(公告)号：US10479835B2

公开(公告)日：2019-11-19

申请号：US15743549

申请日：2016-07-12

Applicant: H. Lundbeck A/S

Inventor： Lars Christian Biilmann Rønn ,  Ibrahim John Malik ,  Jeffrey B. Stavenhagen ,  Søren Christensen ,  Jan Egebjerg ,  Arnout Gerritsen ,  Edward Van Den Brink ,  Paul Parren ,  Rob De Jong

IPC: C07K16/00 ,  A61K51/10 ,  C07K16/28 ,  A61P25/28 ,  A61K39/395 ,  A61K39/00

Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).